GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (STU:SU6) » Definitions » Total Liabilities

Surmodics (STU:SU6) Total Liabilities : €54.1 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Surmodics Total Liabilities?

Surmodics's Total Liabilities for the quarter that ended in Mar. 2024 was €54.1 Mil.

Surmodics's quarterly Total Liabilities declined from Sep. 2023 (€61.68 Mil) to Dec. 2023 (€53.27 Mil) but then increased from Dec. 2023 (€53.27 Mil) to Mar. 2024 (€54.15 Mil).

Surmodics's annual Total Liabilities increased from Sep. 2021 (€46.33 Mil) to Sep. 2022 (€50.47 Mil) and increased from Sep. 2022 (€50.47 Mil) to Sep. 2023 (€61.68 Mil).


Surmodics Total Liabilities Historical Data

The historical data trend for Surmodics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Total Liabilities Chart

Surmodics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 33.91 32.01 46.33 50.47 61.68

Surmodics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 59.41 70.60 61.68 53.27 54.15

Surmodics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Surmodics's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=22.445+(30.339+3.122
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+5.77+0)
=61.7

Total Liabilities=Total Assets (A: Sep. 2023 )-Total Equity (A: Sep. 2023 )
=174.032-112.356
=61.7

Surmodics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=17.661+(30.047+3.217
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+3.222+0)
=54.1

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=168.181-114.034
=54.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surmodics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Surmodics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Surmodics (STU:SU6) Business Description

Traded in Other Exchanges
Address
9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.

Surmodics (STU:SU6) Headlines

No Headlines